Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | KRAS | P01116 | 1/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1779420 | 0.83 | ALDH1A1 (0.51) | SMN1; SMN2 | |
| SCHEMBL30578254 | 0.81 | DGAT1 (0.38) | KRAS | |
| SCHEMBL29119637 | 0.81 | DGAT1 (0.38) | KRAS | |
| SCHEMBL31748392 | 0.81 | DGAT1 (0.35) | SMN1; SMN2GAA | |
| SCHEMBL31748712 | 0.80 | DGAT1 (0.38) | SMN1; SMN2GAANPSR1 | |
| SCHEMBL22165441 | 0.79 | XDH (0.34) | XDH | |
| SCHEMBL22803875 | 0.79 | POLB (0.37) | SMN1; SMN2 | |
| SCHEMBL1049931 | 0.79 | KRAS (0.41) | SMN1; SMN2GAAKRAS | |
| SCHEMBL30138980 | 0.79 | DGAT1 (0.41) | SMN1; SMN2GAANPSR1 | |
| SCHEMBL28906224 | 0.79 | DGAT1 (0.41) | SMN1; SMN2GAANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388571-A1 | AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF | BIOLEXIS THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388571-A1 | AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF | PRKAB2, PRKAB1, PRKAR2B | SMN1; SMN2 2986/4885GAA 3152/4885NPSR1 3520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.